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However, its use outside the National Emphysema Treatment Trial remains poorly understood.
There are no national studies describing the current use of PR among patients with COPD in the United States. Using a 5% national sample of fee-for-service Medicare beneficiaries, we examined national trends and factors associated with the use of PR in older adults with COPD between 2003 and 2012. We hypothesized an increase in PR in patients with COPD after 2010, the year in which the Centers for Medicare & Medicaid Services (CMS) began reimbursing for PR services.
METHODS

Data Source
This was a retrospective study of PR utilization in subjects with COPD using a 5% Medicare beneficiary population, 2003 to 2012. More than 98% of adults in the United States ≥ 65 years are enrolled in Medicare, which comprises > 45 million beneficiaries. The CMS selects a random sample of 5% Medicare beneficiaries on the basis of the eighth and ninth digits (05, 20, 45, 70, 95) of their health insurance claim number, and this standard data available for research purposes has been shown to be representative of the whole cohort. 10 This study was approved by the University of Texas Medical Branch Institutional Review Board, and informed consent was not required because of the nature of the study. All records were deidentified before analysis. Data from multiple files were used for this study: (1) Denominator File (Medicare enrollment information and demographic data); (2) Medicare Provider Analysis and Review File (claims for hospital inpatient and skilled nursing facility stays); (3) Outpatient Standard Analytic File (hospital outpatient services); and (4) 100% Physician/Supplier File (physicians and other medical services). 10 
Study Cohort
A patient met the diagnosis of COPD who had any of the following: (1) at least 2 outpatient or consultation visits (evaluation and management codes 99201-99205 and 99211-99215) with an encounter diagnosis of COPD at least 30 days apart within a year; (2) 1 acute care hospitalization with a primary discharge diagnosis of COPD on the basis of the following International Classification of Diseases, Ninth Revision (ICD-9) codes: 491.x (chronic bronchitis), 492.x (emphysema), or 496 (chronic airway obstruction); or 3) an acute care hospitalization for respiratory failure (ICD-9 codes 518.81, 518.82, and 518.84) as the primary discharge diagnosis and COPD listed as the secondary diagnosis. The index date was defined as the earliest COPD encounter during the calendar year.
A separate denominator file of beneficiaries with COPD was created for each calendar year (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Each file was composed of participants in the year of interest who (1) had a diagnosis of COPD; (2) were ≥ 66 years; (3) had complete Medicare enrollment (Part A, Part B) in the year before and the year of interest or until death; (4) were not enrolled in a health maintenance organization; (5) were not a resident of a nursing facility in the year before and the year of interest or until death; and (6) were a resident in 1 of the 9 geographic regions in the United States.
Study Variables
Medicare enrollment files were used to categorize subjects by age (66-74, 75-84, and ≥ 85 years), sex (male and female), and race/ethnicity (white, black, and other). Medicaid eligibility (state buy-in) in the enrollment file was used as a proxy for low socioeconomic status. A comorbidity score (0, 1, 2, or ≥ 3) was generated using the Elixhauser comorbidity score (excluding COPD) from inpatient and outpatient billing data. 11 , 12 Geographic region was divided into 9 CMS regions.
Outpatient physician visits to a primary care physician (PCP) or to a pulmonary specialist during the 365 days before the index date, defined as the first visit with COPD, were calculated. A PCP physician included any of the following specialties: family medicine, general practice, internal medicine, and geriatrics. Beneficiaries who had a PCP visit and a pulmonary physician visit were considered as being comanaged by a PCP and a pulmonary specialist; those who had a visit to a non-PCP or a nonpulmonary physician were considered as having an "other" physician.
Outcome Measure
The outcome of interest was unique days of PR performed in each calendar year of interest for persons with COPD. PR was identified through the health care common procedure coding system (HCPCS) codes G0237, G0238, G0239, and G0424 (after year 2010) or the current procedural terminology codes 97001, 97003, 97110, 97116, 97124, 97139, 97150, 97530, 97535, and 97537, with primary ICD-9 diagnosis codes 491.x, 492.x, or 496.x.
Statistical Analysis
Patient characteristics were summarized from 2003 to 2012 using counts and percentages of categorical variables. A given patient with COPD could receive PR in multiple years during the study period. To adjust for clustering of outcome (ie, PR) in the same patient over multiple years, an estimate equation with binomial distribution model was built. This model was also adjusted for patient (age, sex, race, region, and comorbidity) and provider (type of provider) characteristics. We randomly selected 1 hospital per patient per year to examine the receipt of PR use after hospitalization for COPD. All analyses were performed using SAS version 9.2 (SAS Inc, Cary, NC). All reported P values were 2-sided, with P < .05 considered statistically significant.
RESULTS
Baseline characteristics of the study cohort in select years are presented in Table 1 . The number of COPD beneficiaries remained stable overall during the study period ranging from 33,526 to 33,446 individuals; however, the number of beneficiaries with COPD utilizing PR increased from 870 in 2003 to 1239 in 2012. Overall, the percentage of persons with COPD utilizing PR remained low: only 3.70% in 2012.
The largest percentage increases in PR use from 2003 to 2012 were in individuals older than 75 years, males, those of black race, and those with more comorbidities and higher socioeconomic status. However, these increases were of small magnitude. Geographically, PR use in subjects with COPD increased across all regions from 2003 to 2012, except in the West South Central region, where it decreased from 2.72% to 2.66%. Increase in PR use ranged from 0.27% in the East South Central regions to 2.42% in the Mountain region.
The majority of patients with COPD were managed by a PCP alone or comanaged with a pulmonary physician (84.8% in 2012). The largest percentage of individuals who used PR were managed by a pulmonary physician alone or comanaged with a PCP (89.2% in 2012). Subjects comanaged by a PCP and a pulmonary physician showed the largest percentage increase in use of PR over time. Table 2 shows the number of days with PR claims per person who received PR by calendar year over the study period. Among patients who received PR, the majority of patients participated in > 8 PR days throughout the study period. The percentage of subjects participating in 1 to 4 and > 8 PR days increased slightly over the study period ( < 1%). Subjects receiving 5 to 8 PR days decreased from 14.37% to 12.83% during the study period. Table 3 presents the multivariable analysis of factors associated with PR use in patients with COPD. Younger persons (66-74 years), males, those of higher socioeconomic class, and those with more comorbidities had higher odds of participating in PR. After adjusting for other relevant factors, compared with 2003, subjects in 2012 had 35% higher odds (OR = 1.35; 95% CI = 1.24-1.48) of participating in PR. Beneficiaries comanaged by both a PCP and a pulmonary physician had a significantly increased odds of PR participation (OR = 2.23; 95% CI = 2.13-2.33) over those seen by a PCP only.
Finally, we examined the percentage of subjects who participated in PR within 30 days after a hospitalization for COPD. Only 0.59% in 2003 and 0.62% in 2012 had a claim for PR after hospitalization for COPD, suggesting most PR use is after 30 days of hospitalization and/or referred from an outpatient setting.
DISCUSSION
We report the use of PR over time in a Medicare population with COPD. From 2003 to 2012, patients enrolled in PR increased modestly. Among those who participated (3.7%) in PR, most completed at least 8 sessions of the program. However, despite becoming a reimbursed benefit under Medicare since 2010, PR use remains low.
Our finding of low use of PR is consistent with prior international surveys that reported 1% to 2% use of PR in patients with COPD. 13 , 14 The modest increase in PR noted in this study is likely multifactorial. The American Association of Cardiovascular and Pulmonary Rehabilitation estimates that there are more than 1000 PR programs in the United States, a number which continues to grow. 15 However, an international study evaluating accessibility to PR programs estimated that ≤ 1.2% of the COPD population could receive PR, if all available facilities operated at capacity. 16 The majority of PR programs are outpatient and affiliated with hospitals, but use of home and community-based programs extend PR benefits beyond these, mainly in urban settings. 16 This is the likely explanation of regional variation of utilization of PR in our population.
Any symptomatic patient with lung disease qualifies for PR; however, specific circumstances should prompt a PR referral. Recent data indicate an increase in oxygen therapy since 2001, as over 40% of COPD patients had at least 1 durable medical equipment claim for oxygen by 2010. 17 Prescription of oxygen should serve as a reminder to consider PR. Patients with a history of COPD exacerbation have increased odds of future exacerbations, which is also the most common reason for PR nonadherence. 18 , 19 Referral to PR after a recent COPD exacerbation is safe and reduces hospital admission, emergency department www.jcrpjournal.com Elixhauser comorbidity components: chronic pulmonary disease, congestive heart failure, valvular disease, pulmonary circulation disorders, peripheral vascular disorders, hypertension, paralysis, other neurological disorders, diabetes-uncomplicated, diabetes-complicated, hypothyroidism, renal failure, liver disease, peptic ulcer disease excluding bleeding, AIDS (acquired immune deficiency syndrome), lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid arthritis/collagen vascular diseases, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression. www.jcrpjournal.com visits, and unscheduled physician visits. 20 Only 0.62% of patients in 2012 had a claim of PR after hospitalization for COPD in our cohort. This may represent an opportunity to improve disease management by early referral to a PR program. In contrast, prescription sales of COPD inhalers increased from 6% to up to 30% over the last decade whereas the use of PR remains low. 21 PR referral should be considered when adding long-acting bronchodilators and for patients hospitalized for acute exacerbation of COPD.
Several factors need to be addressed to increase PR participation. Fewer than 25% of COPD patients are evaluated by a pulmonary physician, who account for the majority of PR referrals. 16 , 22 PCPs diagnose and manage the majority of patients with COPD. However, a recent survey showed that, although 32% of PCPs had PR available, only 3% thought PR was beneficial for patients and were less likely to refer patients to PR. 13 , 22 , 23 Other cited reasons for low PCP referral were lack of PR awareness, unclear referral process, and questioning the need to do more to promote exercise behavior change. 24 Patient factors associated with low PR participation include belief that their disease was too mild or too severe to benefit from PR, fear that PR would be detrimental to their health, or inability to attend related to lack of transportation or social support. 14 , 18 , 25 Promoting PR will require a multifactorial approach to include physician and patient education, improved program access, and structures to encourage enrollment and adherence.
PR clearly has improved patient-centered outcomes, but it also has a role in the changing environment of health care reimbursement. Starting in financial year 2015, the CMS added COPD to the list of conditions subject to penalties for readmissions under the Hospital Readmission Reduction Program. 26 In addition, the first phase of implementation of the Bundled Payments for Care Improvement initiative began in 2013. Compared with the traditional feefor-service reimbursement model, this model links a single payment to the multiple services beneficiaries receive during initial and subsequent related episodes of care. 27 The majority of the economic burden in caring for COPD is due to hospitalization for acute exacerbations. 28 , 29 PR has been shown to reduce COPDrelated emergency department visits, hospitalizations, and unscheduled physician visits, so PR provides an overall cost-effective management strategy for a health care system. 3, 8, 28, 30, 31 As we shift from volumeto value-based reimbursement, it is prudent for every health system to offer hospital-or community-based PR services to patients with COPD. Products are under development to offer low-cost PR applications for patients who are technologically competent and/ or in a health care system without a PR program in the vicinity. [32] [33] [34] Strengths of this study include a large sample size and a nationally representative cohort of individuals. There are several limitations in our study. Our data do not identify the number of suitable patients with COPD who might benefit from PR. However, COPD management guidelines suggest that any patient with COPD with respiratory symptoms, reduced exercise tolerance, or restriction in activities because of the disease should be considered for a PR referral. 5-8 , 30 Administrative data also do not indicate the number of referrals, only the number of participating patients. International survey data show that only 3% to 16% of suitable candidates with COPD are referred for PR and up to half of these referred patients never attend a single session of PR.
14 , 18 Therefore, we cannot discern whether the modest increase in PR may be due to a greater number of referred candidates or an inherent rise in PR sessions because of re-enrollment of past participants. In addition, claims data can only indicate the number of sessions submitted for payment and do not give any information on the quality of PR programs. PR Elixhauser comorbidity components: chronic pulmonary disease, congestive heart failure, valvular disease, pulmonary circulation disorders, peripheral vascular disorders, hypertension, paralysis, other neurological disorders, diabetes-uncomplicated, diabetes-complicated, hypothyroidism, renal failure, liver disease, peptic ulcer disease excluding bleeding, AIDS (acquired immune deficiency syndrome), lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid arthritis/collagen vascular diseases, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression.
